Daré Bioscience, Inc.
DARENext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for DARE. That does not mean none is planned.
Get an email about DARE's next catalysts
Track Daré Bioscience (DARE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
DARE Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.09 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DARE-BV1clindamycin phosphate vaginal | Phase 3 | Bacterial Vaginosis | - | - |
Frequently asked questions
What is in Daré Bioscience, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Daré Bioscience, Inc.'s (DARE) pipeline across Phase 3. Its lead program is DARE-BV1clindamycin phosphate vaginal (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Daré Bioscience, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Daré Bioscience, Inc. (DARE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track DARE biotech catalysts?→
Add DARE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Daré Bioscience, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.